

L Number	Hits	Search Text	DB	Time stamp
1	7466	interferon and immune same disease	USPAT; US-PGPUB	2003/07/25 13:03
2	4682	(interferon and immune same disease) and (oral or orally) same (administration or administering)	USPAT; US-PGPUB	2003/07/25 13:03
3	0	((interferon and immune same disease) and (oral or orally) same (administration or administering)) and 424.ccls.	USPAT; US-PGPUB	2003/07/25 13:03
5	973	interferon same immune same disease	USPAT; US-PGPUB	2003/07/25 13:03
6	555	(interferon same immune same disease) and (oral or orally) same (administration or administering)	USPAT; US-PGPUB	2003/07/25 13:05
7	0	((interferon same immune same disease) and (oral or orally) same (administration or administering)) and 424.ccls.	USPAT; US-PGPUB	2003/07/25 13:04
8	238	((interferon same immune same disease) and (oral or orally) same (administration or administering)) and 424/\$.ccls.	USPAT; US-PGPUB	2003/07/25 13:04
9	14	(interferon same immune same disease) same (oral or orally) same (administration or administering)	USPAT; US-PGPUB	2003/07/25 13:05

AN 86300315 MEDLINE
DN 86300315
TI [Alpha interferon in condylomata acuminata and juvenile diabetes mellitus].
Interferon-alpha bei Condylomata acuminata und juvenilem Diabetes mellitus.
AU Gross G; Roussaki A; Ikenberg H; Drees N
SO DEUTSCHE MEDIZINISCHE WOCHENSCHRIFT, (1986 Sep 5) 111 (36) 1351-5.
Journal code: ECL. ISSN: 0012-0472.
CY GERMANY, WEST: Germany, Federal Republic of
DT Journal; Article; (JOURNAL ARTICLE)
LA German
FS Priority Journals; Cancer Journals
EM 198612
AB Persistent condylomata acuminata in a 21-year-old patient with diabetes mellitus were treated with highly purified interferon-alpha (IFN-alpha) obtained by recombinant DNA technology. Daily dose was 1.5×10^6 IU, given subcutaneously. Already during treatment the condylomata regressed. Two weeks after the end of therapy, i.e. after a total dose of 10.5×10^6 IU IFN-alpha, all condylomata had completely receded. Blood glucose levels remained constant with concomitant insulin therapy. Toxic side-effects or antibodies to IFN-alpha were not observed.